Dawn Wilson, DO
Obstetrics & Gynecology · Yukon, OKNPI 1033209036
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,938 of the $36,064 with a category attached, or 85.8%. AbbVie accounts for 95.1% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $25,284 and has fallen 99.5% since, to $114 in 2025. Among obstetrics & gynecology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $119.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Mayne Pharma Commercial LLC$487
- Therapeuticsmd, Inc.$183
- Pfizer$135
- Astellas Pharma US Inc$113
- Antares Pharma, Inc.$109
- plus $740 from 23 others
What the payments were for
- Speaking & faculty fees$30,93886%
- Travel & lodging$1,0293%
- Food & beverage$4,09711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 184 | $34,296 |
| Mayne Pharma Commercial LLC | 41 | $487 |
| Therapeuticsmd, Inc. | 12 | $183 |
| Pfizer | 8 | $135 |
| Astellas Pharma US Inc | 6 | $113 |
| Antares Pharma, Inc. | 6 | $109 |
| Avion Pharmaceuticals | 6 | $96 |
| Currax Pharmaceuticals LLC | 7 | $88 |
| Bayer | 4 | $58 |
| Revance Therapeutics, Inc. | 2 | $48 |
| Amgen | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Hologic Sales And Service, LLC | 1 | $37 |
| Acella Pharmaceuticals, LLC | 2 | $35 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Novo Nordisk | 2 | $30 |
| Scynexis, Inc. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Mylan Pharmaceuticals Inc. | 1 | $22 |
| Myovant Sciences Inc. | 1 | $21 |
| Coopersurgical, Inc. | 1 | $18 |
| Nalpropion Pharmaceuticals LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Exeltis, USA Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,064 in reported general payments places this provider in the 95th percentile of 396 obstetrics & gynecology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 53 | $55,379 |
| OzempicSemaglutide | 31 | $35,645 |
| MyrbetriqMirabegron | 20 | $17,595 |
| ProgesteroneProgesterone, Micronized | 245 | $13,434 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $7,212 |
| Testosterone Cypionate | 87 | $4,872 |
| Estradiol | 109 | $4,289 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,114 |
| Liothyronine Sodium | 89 | $3,541 |
| Armour ThyroidThyroid,pork | 56 | $2,518 |
| Spironolactone | 107 | $2,223 |
| Np ThyroidThyroid,pork | 31 | $1,847 |
| ValacyclovirValacyclovir Hcl | 18 | $1,483 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $918 |
| Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12) | 26 | $861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $30 | $35,64531 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $17,59520 claims |
| Boehringer IngelheimGlyxambi | $16 | $7,21212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $16 | $4,11411 claims |
| AbbVieArmour Thyroid | $34,296 | $2,51856 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $35 | $1,84731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 obstetrics & gynecology providers in Oklahoma.
Other obstetrics & gynecology in Yukon
- Joseph MitroYukon$6K
- Tori OdanielOklahoma City$917K
- Kathleen MooreOklahoma City$795K
- Joseph NemcokTulsa$632K
- Jay WilliamsonTulsa$130K
- John SiegleAda$50K
- Lori HubbardTulsa$41K
- Beverly VavrickaOklahoma City$22K
- Micah RelicTulsa$20K
- Monica ReidOklahoma City$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.